Tesamorelin

Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH) that carries an added trans-3-hexenoic acid group. It is supplied as a 5 mg lyophilized powder for laboratory research use only.

Research applications

Tesamorelin is used in studies of GHRH receptor signaling and growth hormone axis biology. Other research topics include lipid and fat-tissue metabolism, peripheral nerve models, and brain GABA levels.

Pathway and mechanistic context

As a GHRH analog, tesamorelin is described as acting on the GHRH receptor in the pituitary. The added acyl group is reported to make the molecule more stable in plasma than native GHRH.

Preclinical summary

Laboratory and mouse studies have examined its stability, bioavailability, and signaling. Published human studies exist for this molecule, but this product is for laboratory research only and none of that work applies to it.

Form and analytical testing

Supplied as a lyophilized powder. Identity and purity are normally confirmed by HPLC and mass spectrometry. Refer to the Certificate of Analysis for the lot you receive.

References

1. A. Mangili, J. Falutz, J.-C. Mamputu, M. Stepanians, and B. Hayward, “Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat,” PloS One, vol. 10, no. 10, p. e0140358, 2015. Source
2. J. Falutz et al., “Metabolic effects of a growth hormone-releasing factor in patients with HIV,” N. Engl. J. Med., vol. 357, no. 23, pp. 2359–2370, Dec. 2007. Source
3. T. L. Stanley et al., “Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin,” Clin. Infect. Dis., vol. 54, no. 11, pp. 1642–1651, Jun. 2012. Source
4. V. Rochira and G. Guaraldi, “Growth hormone deficiency and human immunodeficiency virus,” Best Pract. Res. Clin. Endocrinol. Metab., vol. 31, no. 1, pp. 91–111, 2017. Source
5. S. H. Tuffaha et al., “Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury,” Expert Opin. Ther. Targets, vol. 20, no. 10, pp. 1259–1265, Oct. 2016. Source
6. S. D. Friedman et al., “Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging,” JAMA Neurol., vol. 70, no. 7, pp. 883–890, Jul. 2013. Source

Peptides are shipped lyophilized (freeze-dried), a state that keeps them stable in transit. Keep vials cold and away from light on arrival.

• Short term: refrigeration below 4°C (39°F) is generally suitable for lyophilized material held for days to months.
• Long term: a freezer at -80°C (-112°F) is preferred for storage over several months or years.
• After reconstitution: keep the vial refrigerated. Reconstituted material is generally kept for up to 30 days.